ZBH:NYE-Zimmer Biomet Holdings Inc.

EQUITY | Medical Devices | New York Stock Exchange

Last Closing Price

USD 116.42

Change

0.00 (0.00)%

Market Cap

USD 23.84B

Volume

1.34M

Average Target Price

USD 129.37 (+11.12%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Zimmer Biomet Holdings Inc is engaged in designing, manufacturing & marketing orthopaedic reconstructive products; sports medicine, biologics, extremities & trauma products; spine, bone healing, craniomaxillofacial & thoracic products & dental implants.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-05-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

N/A

USD 134.02B
MDT Medtronic plc.

N/A

USD 117.66B
SYK Stryker Corporation

N/A

USD 68.83B
BSX Boston Scientific Corporation

N/A

USD 51.90B
EW Edwards Lifesciences Corporati..

N/A

USD 35.98B
SNN Smith & Nephew SNATS Inc.

N/A

USD 18.25B
PEN Penumbra Inc.

N/A

USD 4.95B
GMED Globus Medical Inc. Class A

N/A

USD 4.22B
ITGR Integer Holdings Corporation

N/A

USD 2.31B
NVRO Nevro Corp.

N/A

USD 1.90B

ETFs Containing ZBH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.24% 63% D 59% F
Dividend Return 0.23% 17% F 8% F
Total Return 12.48% 56% F 55% F
Trailing 12 Months  
Capital Gain 1.68% 36% F 63% D
Dividend Return 0.84% 33% F 12% F
Total Return 2.52% 36% F 54% F
Trailing 5 Years  
Capital Gain 15.71% 18% F 66% D
Dividend Return 4.63% 43% F 14% F
Total Return 20.35% 18% F 50% F
Average Annual (5 Year Horizon)  
Capital Gain 2.71% 14% F 61% D-
Dividend Return 3.54% 14% F 45% F
Total Return 0.83% 43% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 12.21% 79% C+ 58% F
Risk Adjusted Return 29.01% 21% F 43% F
Market Capitalization 20.27B 69% D+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -62.59 94% A 95% A
Price/Book Ratio 1.94 94% A 39% F
Price / Cash Flow Ratio 3.38 69% D+ 37% F
Price/Free Cash Flow Ratio 18.13 63% D 32% F
Management Effectiveness  
Return on Equity -3.19% 31% F 19% F
Return on Invested Capital 5.37% 50% F 33% F
Return on Assets -1.48% 38% F 17% F
Debt to Equity Ratio 81.50% 31% F 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.